Table 2.

Landmark trials that established FFR as the most widely used invasive physiologic test.

Trial	DEFER [ 34 , 35 ]	FAME [ 32 ]	FAME 2 [ 33 ]
Design	RCT, multi-centric	RCT, multi-centric	RCT, multi-centric
Number of patients	325	1005	1220
Clinical syndrome	Stable CAD	Stable multi-vessel CAD	Stable CAD
Primary endpoint	Absence of all-cause mortality, MI, CABG, PCI, and any procedure-related complication necessitating major intervention or prolonged hospital stay at 2 years	Death, nonfatal MI, and repeat revascularization at 1 year	Death from any cause, nonfatal MI, unplanned hospitalization leading to urgent revascularization during the first 2 years
Key finding	Deferring PCI in lesions with FFR >0.75 is safe	FFR-guided PCI outperformed angiography guided PCI	FFR-guided PCI plus optimal medical therapy outperformed medical therapy alone